Fred Jacobs | Chief Executive Officer and Co Founder

Fred Jacobs, Chief Executive Officer and Co Founder, TYG

Fred earned his accounting degree at the University of Maryland and started his professional career with PwC in the Washington DC office where he worked on significant assignments like the audit and divestiture of ATT. Fred was transferred to the Honolulu, Hawaii office of PwC to work with Pacific Rim clients. Fred moved to healthcare as the Chief Operating Officer of Island Care, a US Health Maintenance Organization. While at Island Care, Fred was instrumental in the pre-IPO activities for a biotechnology company called Aphton Corporation. Aphton corporation had its IPO and listed on the Nasdaq market, in 1991. Fred became their Chief Financial Officer. Aphton raised $230M that was invested in gastrin hormone therapy and other hormone therapies. Capitalizing on that experience, Fred co-founded Astrimmune to carry on the important work of gastrin hormone neutralisation. Fred co-founded TYG Oncology to enable the development of TYG100, a product that promises to provide a well tolerated non-chemo alternative or adjuvant for pancreatic cancer patients and for other gastrointestinal cancers, using gastrin neutralisation therapy.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 12:35

Active checkpoint control therapeutics will supersede most monoclonal antibodies

back to speakers